Keywords: Nin-Hodgkins lymphoma, Decision Resources, Roche, Rituxan, Rituximab, GlaxoSmithKline, Arzerra, Biosimilars

Non-Hodgkins lymphoma drug market set to more than double by 2019

Article | 05 May 2011

Print This

Driven by the launches of premium-priced therapies, the non-Hodgkin’s lymphoma drug market will more than double over the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in